Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy

Journal of Molecular Endocrinology

Volumn 58, Issue 4, 2017, Pages R225-R240

  Ritchie, Rebecca H ^a,b   Zerenturk, Eser J ^a   Prakoso, Darnel ^a,c   Calkin, Anna C ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiomyopathy; Diabetes; Heart; Lipid metabolism; Mouse models

Indexed keywords

CALMODULIN; INSULIN; INSULIN 2; LIPID; STREPTOZOCIN; UNCLASSIFIED DRUG; FATTY ACID; GLUCOSE;

CELL FUNCTION; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; HEART; HUMAN; HYDROLYSIS; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; MITOCHONDRION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIAC MUSCLE; COMPLICATION; DISEASE MODEL; GENE THERAPY; GENETICS; HEART FAILURE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOLOGY; PROCEDURES;

ANIMALS; CALMODULIN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FATTY ACIDS; GENETIC THERAPY; GLUCOSE; HEART FAILURE; HUMANS; INSULIN-SECRETING CELLS; LIPID METABOLISM; MICE; MITOCHONDRIA; MYOCARDIUM;

EID: 85019842658     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-16-0249     Document Type: Review

References (102)

1. American Diabetes Association 2009 Diagnosis and classification of diabetes mellitus. Diabetes Care 32 (Supplement 1) S62-S67. (doi:10.2337/dc09-S062)
2. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ & Neufer PD 2009 Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. Journal of the American College of Cardiology 54 1891-1898. (doi:10.1016/j.jacc.2009.07.031)
3. Aronson D, Rayfield EJ & Chesebro JH 1997 Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Annals of Internal Medicine 126 296-306. (doi:10.7326/0003-4819-126-4-199702150-00006)
4. Avogaro A, Nosadini R, Doria A, Fioretto P, Velussi M, Vigorito C, Saccà L, Toffolo G, Cobelli C & Trevisan R 1990 Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. American Journal of Physiology 258 18.
5. Baseler WA, Dabkowski ER, Jagannathan R, Thapa D, Nichols CE, Shepherd DL, Croston TL, Powell M, Razunguzwa TT, Lewis SE, et al. 2013 Reversal of mitochondrial proteomic loss in Type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 304 65.
6. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD & Kassiri Z 2009 Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. American Journal of Physiology: Heart and Circulatory Physiology 297 108.
7. Bayeva M, Sawicki KT & Ardehali H 2013 Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. Journal of the American Heart Association 2 e000433. (doi:10.1161/JAHA.113.000433)
8. Bing RJ, Siegel A, Ungar I & Gilbert M 1954 Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. American Journal of Medicine 16 504-515. (doi:10.1016/0002-9343(54)90365-4)
9. Boudina S & Abel ED 2007 Diabetic cardiomyopathy revisited. Circulation 115 3213-3223. (doi:10.1161/CIRCULATIONAHA.106.679597)
10. Bugger H & Abel ED 2014 Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57 660-671. (doi:10.1007/s00125-014-3171-6)
11. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, Yun UJ, McQueen AP, Wayment B, Litwin SE, et al. 2008 Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 57 2924-2932. (doi:10.2337/db08-0079)
12. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC & Abel ED 2009 Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 58 1986-1997. (doi:10.2337/db09-0259)
13. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ & Kelly DP 2007 Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. Journal of Clinical Investigation 117 3930-3939.
14. Chavali V, Tyagi SC & Mishra PK 2014 Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/-Akita hearts. Cell Biochemistry and Biophysics 68 25-35. (doi:10.1007/s12013-013-9679-4)
15. Dong B, Qi D, Yang L, Huang Y, Xiao X, Tai N, Wen L & Wong FS 2012 TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. American Journal of Physiology: Heart and Circulatory Physiology 303 42.
16. Doria A, Nosadini R, Avogaro A, Fioretto P & Crepaldi G 1991 Myocardial metabolism in type 1 diabetic patients without coronary artery disease. Diabetic Medicine 8 Spec No 7.
17. Epstein PN, Overbeek PA & Means AR 1989 Calmodulin-induced early-onset diabetes in transgenic mice. Cell 58 1067-1073. (doi:10.1016/0092-8674(89)90505-9)
18. Epstein PN, Ribar TJ, Decker GL, Yaney G & Means AR 1992 Elevated beta-cell calmodulin produces a unique insulin secretory defect in transgenic mice. Endocrinology 130 1387-1393. (doi:10.1210/en.130.3.1387)
19. Fang ZY, Prins JB & Marwick TH 2004 Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews 25 543-567. (doi:10.1210/er.2003-0012)
20. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, et al. 2002 The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. Journal of Clinical Investigation 109 121-130. (doi:10.1172/JCI0214080)
21. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW & Kelly DP 2003 A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. PNAS 100 1226-1231. (doi:10.1073/pnas.0336724100)
22. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, et al. 2004 Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. Journal of Molecular and Cellular Cardiology 37 959-968. (doi:10.1016/j.yjmcc.2004.07.008)
23. Glass CK & Witztum JL 2001 Atherosclerosis. The road ahead. Cell 104 503-516.
24. Glatz JF, Angin Y, Steinbusch LK, Schwenk RW & Luiken JJ 2013 CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids 88 71-77. (doi:10.1016/j.plefa.2012.04.009)
25. Goh SY & Cooper ME 2008 Clinical review: the role of advanced glycation end products in progression and complications of diabetes. Journal of Clinical Endocrinology and Metabolism 93 1143-1152. (doi:10.1210/jc.2007-1817)
26. Goldberg IJ, Trent CM & Schulze PC 2012 Lipid metabolism and toxicity in the heart. Cell Metabolism 15 805-812. (doi:10.1016/j.cmet.2012.04.006)
27. Gotzsche O, Darwish A, Gotzsche L, Hansen LP & Sorensen KE 1996 Incipient cardiomyopathy in young insulin-dependent diabetic patients: a seven-year prospective Doppler echocardiographic study. Diabetic Medicine 13 834-840. (doi:10.1002/(SICI)1096-9136(199609)13:9<834::AID-DIA225>3.0.CO;2-M)
28. Habets DD, Coumans WA, Voshol PJ, den Boer MA, Febbraio M, Bonen A, Glatz JF & Luiken JJ 2007 AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochemical and Biophysical Research Communications 355 204-210. (doi:10.1016/j.bbrc.2007.01.141)
29. Hammer S, Jonker JT, Lamb HJ, van der Meer RW, Zondag W, Sepers JM, de Roos A, Smit JW & Romijn JA 2008 Short-term hyperglycemic dysregulation in patients with type 1 diabetes does not change myocardial triglyceride content or myocardial function. Diabetes Care 31 1613-1614. (doi:10.2337/dc08-0513)
30. Han X, Yang J, Yang K, Zhao Z, Abendschein DR & Gross RW 2007 Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: a shotgun lipidomics study. Biochemistry 46 6417-6428. (doi:10.1021/bi7004015)
31. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C & Gropler RJ 2006 Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. Journal of the American College of Cardiology 47 598-604. (doi:10.1016/j.jacc.2005.09.030)
32. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, Kiriazis H, Du XJ & Ritchie RH 2010 Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 59 1512-1520. (doi:10.2337/db09-1456)
33. Huynh K, Bernardo BC, McMullen JR & Ritchie RH 2014 Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacology and Therapeutics 142 375-415. (doi:10.1016/j.pharmthera.2014.01.003)
34. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S & Selby JV 2001 Glycemic control and heart failure among adult patients with diabetes. Circulation 103 2668-2673. (doi:10.1161/01.CIR.103.22.2668)
35. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, et al. 2013 A largely random AAV integration profile after LPLD gene therapy. Nature Medicine 19 889-891. (doi:10.1038/nm.3230)
36. Kamp F, Zakim D, Zhang F, Noy N & Hamilton JA 1995 Fatty acid flip-flop in phospholipid bilayers is extremely fast. Biochemistry 34 11928-11937. (doi:10.1021/bi00037a034)
37. Kannel WB & McGee DL 1979 Diabetes and cardiovascular disease. The Framingham study. JAMA 241 2035-2038. (doi:10.1001/jama.1979.03290450033020)
38. Kannel WB, Hjortland M & Castelli WP 1974 Role of diabetes in congestive heart failure: the Framingham study. American Journal of Cardiology 34 29-34. (doi:10.1016/0002-9149(74)90089-7)
39. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M & Berns KI 1990 Site-specific integration by adeno-associated virus. PNAS 87 2211-2215. (doi:10.1073/pnas.87.6.2211)
40. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, et al. 2008 Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metabolism 7 45-56. (doi:10.1016/j.cmet.2007.10.013)
41. Kralik PM, Ye G, Metreveli NS, Shem X & Epstein PN 2005 Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovascular Toxicology 5 285-292. (doi:10.1385/CT:5:3:285)
42. Kuramoto K, Sakai F, Yoshinori N, Nakamura TY, Wakabayashi S, Kojidani T, Haraguchi T, Hirose F & Osumi T 2014 Deficiency of a lipid droplet protein, perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction. Molecular and Cellular Biology 34 2721-2731. (doi:10.1128/MCB.00133-14)
43. Kusaka Y, Sawai T, Ito M, Oka M, Miyazaki S, Tanaka M & Minami T 2008 Three cases of acute pulmonary thromboembolism diagnosed by transesophageal echocardiography. Masui 57 973-977.
44. LaRocca TJ, Fabris F, Chen J, Benhayon D, Zhang S, McCollum L, Schecter AD, Cheung JY, Sobie EA, Hajjar RJ, et al. 2012 Na+/Ca2+ exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF-kappaB pathway. American Journal of Physiology: Heart and Circulatory Physiology 303 H353-H367. (doi:10.1152/ajpheart.01198.2011)
45. Lehto S, Pyorala K, Miettinen H, Ronnemaa T, Palomaki P, Tuomilehto J & Laakso M 1994 Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. Journal of Internal Medicine 236 291-297. (doi:10.1111/j.1365-2796.1994.tb00799.x)
46. Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA, Arnold JM, Abel ED & Peng T 2011 Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 60 2985-2994. (doi:10.2337/db10-1333)
47. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X & Epstein PN 2002 Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51 174-181. (doi:10.2337/diabetes.51.1.174)
48. Ligeti L, Szenczi O, Prestia CM, Szabo C, Horvath K, Marcsek ZL, van Stiphout RG, van Riel NA, Op den Buijs J, Van der Vusse GJ, et al. 2006 Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy. International Journal of Molecular Medicine 17 1035-1043.
49. Liu GX, Hanley PJ, Ray J & Daut J 2001 Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circulation Research 88 918-924. (doi:10.1161/hh0901.089881)
50. Lu Z, Jiang YP, Xu XH, Ballou LM, Cohen IS & Lin RZ 2007 Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling. Diabetes 56 2780-2789. (doi:10.2337/db06-1629)
51. Mahaney MC, Blangero J, Comuzzie AG, VandeBerg JL, Stern MP & MacCluer JW 1995 Plasma HDL cholesterol, triglycerides, and adiposity. A quantitative genetic test of the conjoint trait hypothesis in the San Antonio Family Heart Study. Circulation 92 3240-3248. (doi:10.1161/01.CIR.92.11.3240)
52. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K & Tochino Y 1980 Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29 1-13. (doi:10.1538/expanim1978.29.1_1)
53. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG & Szczepaniak LS 2007 Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116 1170-1175. (doi:10.1161/CIRCULATIONAHA.106.645614)
54. Mishra PK, Givvimani S, Metreveli N & Tyagi SC 2010 Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. Biochemical and Biophysical Research Communications 401 175-181. (doi:10.1016/j.bbrc.2010.09.006)
55. Nielsen LB, Bartels ED & Bollano E 2002 Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. Journal of Biological Chemistry 277 27014-27020. (doi:10.1074/jbc.M203458200)
56. Novgorodov SA, Riley CL, Yu J, Keffler JA, Clarke CJ, Van Laer AO, Baicu CF, Zile MR & Gudz TI 2016 Lactosylceramide contributes to mitochondrial dysfunction in diabetes. Journal of Lipid Research 57 546-562. (doi:10.1194/jlr.M060061)
57. Park HJ, Zhang Y, Du C, Welzig CM, Madias C, Aronovitz MJ, Georgescu SP, Naggar I, Wang B, Kim YB, et al. 2009 Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice. Circulation Research 105 287-294. (doi:10.1161/CIRCRESAHA.109.193995)
58. Peterson LR, Herrero P, McGill J, Schechtman KB, Kisrieva-Ware Z, Lesniak D & Gropler RJ 2008 Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes 57 32-40. (doi:10.2337/db07-1199)
59. Poornima IG, Parikh P & Shannon RP 2006 Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation Research 98 596-605. (doi:10.1161/01.RES.0000207406.94146.c2)
60. Prathipati P, Metreveli N, Nandi SS, Tyagi SC & Mishra PK 2016 Ablation of matrix metalloproteinase-9 prevents cardiomyocytes contractile dysfunction in diabetics. Frontiers in Physiology 7 93.
61. Pulinilkunnil T, Kienesberger PC, Nagendran J, Waller TJ, Young ME, Kershaw EE, Korbutt G, Haemmerle G, Zechner R & Dyck JR 2013 Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 62 1464-1477. (doi:10.2337/db12-0927)
62. Randle PJ, Garland PB, Hales CN & Newsholme EA 1963 The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 785-789. (doi:10.1016/S0140-6736(63)91500-9)
63. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR & Haider B 1977 Evidence for cardiomyopathy in familial diabetes mellitus. Journal of Clinical Investigation 60 884-899. (doi:10.1172/jci108843)
64. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A & Lamb HJ 2008 Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. Journal of the American College of Cardiology 52 1793-1799. (doi:10.1016/j.jacc.2008.07.062)
65. Rossini AA, Like AA, Chick WL, Appel MC & Cahill GF Jr 1977 Studies of streptozotocin-induced insulitis and diabetes. PNAS 74 2485-2489. (doi:10.1073/pnas.74.6.2485)
66. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW & Grishman A 1972 New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology 30 595-602. (doi:10.1016/0002-9149(72)90595-4)
67. Ruiz M, Coderre L, Lachance D, Houde V, Martel C, Thompson Legault J, Gillis MA, Bouchard B, Daneault C, Carpentier AC, et al. 2016 MK2 deletion in mice prevents diabetes-induced perturbations in lipid metabolism and cardiac dysfunction. Diabetes 65 381-392. (doi:10.2337/db15-0238)
68. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N & Hunter LA 1991 Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO Journal 10 3941-3950.
69. Schulze PC, Drosatos K & Goldberg IJ 2016 Lipid use and misuse by the heart. Circulation Research 118 1736-1751. (doi:10.1161/CIRCRESAHA.116.306842)
70. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH & Taegtmeyer H 2004 Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB Journal 18 1692-1700. (doi:10.1096/fj.04-2263com)
71. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM, Klein JB & Epstein PN 2004 Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. American Journal of Physiology: Endocrinology and Metabolism 287 905. (doi:10.1152/ajpendo.00047.2004)
72. Shen X, Ye G, Metreveli NS & Epstein PN 2005 Cardiomyocyte defects in diabetic models and protection with cardiac-targeted transgenes. Methods in Molecular Medicine 112 379-388. (doi:10.1385/1-59259-879-x:379)
73. Shen X, Zheng S, Metreveli NS & Epstein PN 2006 Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55 798-805. (doi:10.2337/diabetes.55.03.06.db05-1039)
74. Shiroto K, Otani H, Yamamoto F, Huang CK, Maulik N & Das DK 2005 MK2-/-gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. Journal of Molecular and Cellular Cardiology 38 93-97. (doi:10.1016/j.yjmcc.2004.10.018)
75. Song Y, Du Y, Prabhu SD & Epstein PN 2007 Diabetic cardiomyopathy in OVE26 mice shows mitochondrial ROS production and divergence between in vivo and in vitro contractility. Review of Diabetic Studies 4 159-168. (doi:10.1900/RDS.2007.4.159)
76. St-Pierre J, Buckingham JA, Roebuck SJ & Brand MD 2002 Topology of superoxide production from different sites in the mitochondrial electron transport chain. Journal of Biological Chemistry 277 44784-44790. (doi:10.1074/jbc.M207217200)
77. Streicher JM, Ren S, Herschman H & Wang Y 2010 MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circulation Research 106 1434-1443. (doi:10.1161/CIRCRESAHA.109.213199)
78. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, Unger R & Victor RG 2003 Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magnetic Resonance in Medicine 49 417-423. (doi:10.1002/mrm.10372)
79. Szczepaniak LS, Victor RG, Orci L & Unger RH 2007 Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circulation Research 101 759-767. (doi:10.1161/CIRCRESAHA.107.160457)
80. Thomas CM, Yong QC, Seqqat R, Chandel N, Feldman DL, Baker KM & Kumar R 2013 Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clinical Science 124 529-541. (doi:10.1042/CS20120448)
81. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR & Holman RR 1998 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 823-828. (doi:10.1136/bmj.316.7134.823)
82. Ueno M, Suzuki J, Zenimaru Y, Takahashi S, Koizumi T, Noriki S, Yamaguchi O, Otsu K, Shen WJ, Kraemer FB, et al. 2008 Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. American Journal of Physiology: Endocrinology and Metabolism 294 E1109-E1118. (doi:10.1152/ajpendo.00016.2008)
83. UKPDS33 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 837-853. (doi:10.1016/S0140-6736(98)07019-6)
84. Vadvalkar SS, Baily CN, Matsuzaki S, West M, Tesiram YA & Humphries KM 2013 Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a chronic model of type 1 diabetes. Biochemical Journal 449 253-261. (doi:10.1042/BJ20121038)
85. Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, Takata K, Koizumi A & Izumi T 1999 A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. Journal of Clinical Investigation 103 27-37. (doi:10.1172/JCI4431)
86. Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y, Tan Y, Cui W, Liu B, Cui T, et al. 2013 Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. American Journal of Physiology: Heart and Circulatory Physiology 304 H567-H578. (doi:10.1152/ajpheart.00650.2012)
87. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, Bader M, Schultheiss HP & Tschope C 2009 Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58 1373-1381. (doi:10.2337/db08-0329)
88. Wisneski JA, Stanley WC, Neese RA & Gertz EW 1990 Effects of acute hyperglycemia on myocardial glycolytic activity in humans. Journal of Clinical Investigation 85 1648-1656. (doi:10.1172/JCI114616)
89. Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, Sreejayan N, Privratsky JR & Ren J 2006 Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radical Biology and Medicine 40 1419-1429. (doi:10.1016/j.freeradbiomed.2005.12.009)
90. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, Li H, Rathi S, Dong Y, Tian R, et al. 2011 Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60 1770-1778. (doi:10.2337/db10-0351)
91. Xu X, Kobayashi S, Chen K, Timm D, Volden P, Huang Y, Gulick J, Yue Z, Robbins J, Epstein PN, et al. 2013 Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. Journal of Biological Chemistry 288 18077-18092. (doi:10.1074/jbc.M113.474650)
92. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, et al. 2003 Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. Journal of Clinical Investigation 111 419-426. (doi:10.1172/JCI16751)
93. Yan X, Chen J, Zhang C, Zhou S, Zhang Z, Chen J, Feng W, Li X & Tan Y 2015 FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. Journal of Cellular and Molecular Medicine 19 1557-1568. (doi:10.1111/jcmm.12530)
94. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN & Kelly DP 2007 CD36 deficiency rescues lipotoxic cardiomyopathy. Circulation Research 100 1208-1217. (doi:10.1161/01.RES.0000264104.25265.b6)
95. Yao D & Brownlee M 2010 Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59 249-255. (doi:10.2337/db09-0801)
96. Ye G, Metreveli NS, Ren J & Epstein PN 2003 Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52 777-783. (doi:10.2337/diabetes.52.3.777)
97. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC & Epstein PN 2004 Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53 1336-1343. (doi:10.2337/diabetes.53.5.1336)
98. Yoshioka M, Kayo T, Ikeda T & Koizumi A 1997 A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46 887-894. (doi:10.2337/diab.46.5.887)
99. Yu W, Niwa T, Miura Y, Horio F, Teradaira S, Ribar TJ, Means AR, Hasegawa Y, Senda T & Niki I 2002 Calmodulin overexpression causes Ca(2+)-dependent apoptosis of pancreatic beta cells, which can be prevented by inhibition of nitric oxide synthase. Laboratory Investigation 82 1229-1239. (doi:10.1097/01.LAB.0000027921.01548.C5)
100. Zacchigna S, Zentilin L & Giacca M 2014 Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circulation Research 114 1827-1846. (doi:10.1161/CIRCRESAHA.114.302331)
101. Zhang X, Ye G, Duan J, Chen AF & Ren J 2003 Influence of gender on intrinsic contractile properties of isolated ventricular myocytes from calmodulin-induced diabetic transgenic mice. Endocrine Research 29 227-236. (doi:10.1081/ERC-120022318)
102. Zhang L, Keung W, Samokhvalov V, Wang W & Lopaschuk GD 2010 Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochimica et Biophysica Acta 1801 1-22. (doi:10.1016/j.bbalip.2009.09.014)